This work was supported in part by NIH grants K01DK093657 (JMH), R03DK110270 (JMH), and Baylor College of Medicine seed funding (RAB)
As a result of the success of GLP-1s, plan sponsors that cover weight-loss medications have seen a dramatic increase in spending on those drugs in the recent years
Cagrilintide from Novo Nordisk is an amylin analog being studied in combination with semaglutide (the combination is called CagriSema)
Handling and Storage Tips: Keep peptides cold and away from light once received
Most modern CPAP machines auto-adjust within a pressure range, but significant weight loss may require a new sleep study to determine if continued CPAP remains necessary or if a lower pressure range would be appropriate
Semaglutide: Single-Receptor Approach Semaglutide activates the GLP-1 receptor, producing the following effects: Appetite suppression through direct action on hypothalamic neurons that control hunger signaling Delayed gastric emptying that promotes prolonged feelings of fullness after meals Enhanced glucose-dependent insulin secretion from pancreatic beta cells Reduced glucagon secretion (different from glucagon receptor activation) that lowers hepatic glucose output Potential neuroprotective effects currently being studied in Alzheimers disease trials Research by Blundell et al